Catalyst Pharmaceuticals (CPRX) Cash Flow: Operating & Free Cash Flow

Catalyst Pharmaceuticals (CPRX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Catalyst Pharmaceuticals generated $208.67M of operating cash flow and spent $58.00K on capital expenditures. That left free cash flow of $208.61M, down 12.8% from $239.25M a year earlier, or 35.4% of revenue. It repurchased $25.30M of its own shares.

Catalyst Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Catalyst Pharmaceuticals, Inc. (CPRX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	214.33	163.89	71.41	83.08	39.48	74.98	31.88	-34.00	-18.41
Depreciation & Amortization	37.87	37.77	32.88	1.24	0.19	0.89	0.30	0.04	0.05
Deferred Income Tax	-6.85	-9.39	-17.82	4.94	9.32	-32.97	0.00	0.00	0.00
Stock Based Compensation	24.78	22.25	14.25	7.91	6.07	0.00	0.00	3.55	2.41
Change in Working Capital	-60.90	30.91	-37.32	13.73	5.02	-4.11	-1.10	4.71	2.03
Change in Accounts Receivable	-61.00	-11.96	-43.08	-3.82	-0.63	4.55	-10.54	0.00	0.00
Change in Inventory	-18.09	-3.90	-4.74	1.07	-3.22	-2.69	-1.90	-0.06	0.00
Change in Accounts Payable	-5.39	1.80	10.82	1.21	-1.49	0.14	1.78	0.39	1.01
Change in Other Working Capital	23.59	44.98	-6.13	15.28	0.29	-6.11	9.56	4.37	1.02
Other Operating Activities	-0.56	-5.63	62.38	5.16	0.29	6.25	3.53	3.68	0.19
Net Cash from Operating Activities	208.67	239.81	143.60	116.05	60.37	45.03	34.61	-25.70	-13.74
Investing Activities
Capital Expenditures	-0.06	-0.56	-198.52	-0.03	-1.02	-0.01	-0.02	-0.09	0.00
Acquisitions	0.00	0.00	-198.29	10.00	0.00	0.00	0.00	0.00	0.00
Purchases of Investments	0.00	0.00	-13.47	-10.00	-10.00	-10.00	-34.73	-36.80	0.00
Sales/Maturities of Investments	0.00	0.00	-81.51	19.24	0.00	5.00	71.97	21.37	0.00
Other Investing Activities	0.00	0.00	-279.81	-10.00	0.00	0.00	0.00	-14.99	0.00
Net Cash from Investing Activities	-0.06	-0.56	-293.50	9.21	-11.02	-5.01	37.22	-15.53	0.00
Financing Activities
Common Stock Issued	14.67	141.00	2.79	0.00	4.10	0.76	1.12	0.30	53.77
Common Stock Repurchased	-25.30	-0.30	-0.98	-6.91	-12.09	0.00	0.00	0.00	0.00
Other Financing Activities	-6.36	-0.04	-12.67	8.60	-0.15	-0.06	0.00	0.29	3.58
Net Cash from Financing Activities	-16.99	140.67	-10.86	1.69	-8.14	0.70	1.12	0.29	57.35
Summary
Net Change in Cash	191.62	379.92	-160.76	126.95	41.21	40.73	72.95	-40.94	43.60
Cash at Beginning of Period	517.55	137.64	298.40	171.45	130.24	89.51	16.56	57.50	13.89
Cash at End of Period	709.17	517.55	137.64	298.40	171.45	130.24	89.51	16.56	57.50
Free Cash Flow	208.61	239.25	-54.92	116.02	59.35	45.02	34.59	-25.80	-13.74
Supplemental Disclosures
Interest Paid	-	1.40	0.71	-	-	-	-	-	-
Income Taxes Paid	-	68.45	50.46	7.67	3.00	2.79	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Catalyst Pharmaceuticals Cash Flow

What is Catalyst Pharmaceuticals's free cash flow?

Catalyst Pharmaceuticals generated free cash flow of $208.61M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $208.67M minus $58.00K of capital expenditures. That was down 12.8% from $239.25M a year earlier. Free cash flow equaled 35.4% of revenue.

How much does Catalyst Pharmaceuticals spend on capital expenditures?

Catalyst Pharmaceuticals spent $58.00K on capital expenditures in fiscal 2025, compared with $556.00K a year earlier. That equals 0.00% of operating cash flow.

Does Catalyst Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Catalyst Pharmaceuticals returned $25.30M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition